Adult Dosing
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Pediatric Dosing
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
- Safety and efficacy have not been established
Renal Dose Adjustment (Based on CrCl)
- Mild impairment (CrCl = > 60mL/min): No dose adjustments
- Moderate impairment (CrCl = > 30 to < 60 mL/min): Decrease to 12.5 mg PO Daily
- Severe impairment (CrCl = >15 to <30 mL/min) or ESRD (CrCl <15 mL/min) or requiring hemodialysis: 6.25 mg PO Daily
Hepatic Dose Adjustment
- Mild-to-moderate (Child-Pugh A and B) impairment: No dosage adjustments
- Severe (Child-Pugh C) impairment: Dose adjustments not definced
- Acute pancreatitis has been reported with use of alogliptin. Discontinue therapy if pancreatitis is suspected
- Hypersensitivity reactions such as anaphylaxis, angioedema and severe cutaneous adverse reactions have occured in patients treated with alogliptin. If hypersensitivity occurs promptly discontinue therapy, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes
- Fatal and nonfatal hepatic failure has been reported. If liver injury is detected, promptly interrupt therapy and assess patient for probable cause, then treat cause if possible, to resolution or stabilization
- Insulin and insulin secretagogues (eg, sulfonylureas) are known to cause hypoglycemia; therefore, a lower dose of insulin of insulin secretagogue may be needed to minimize hypoglycemia risk
- Patients with type 2 diabetes may have fatty liver disease which may cause liver test abnormalities. Use cautiously in patients with abnormal liver tests
Cautions: use cautiously in
Pregnancy Category:B
Breastfeeding: Safety unknown; as many drugs are excreted in breast milk and because of the potential for serious adverse reactions in nursing infants, manufacturer advises to make a decision whether to discontinue nursing while taking the drug or to discontinue therapy, taking into account the importance of the drug to the mother
